SCHEMBL2972065

SCHEMBL2972065

Clc1nc2ccnn2c(Cl)c1-c1ccsc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 1/20 0.40
KCNN1 Q92952 2/20 0.34
KCNN2 Q9H2S1 2/20 0.34
KCNN3 Q9UGI6 2/20 0.34
PDGFRB P09619 1/20 0.34
PDGFRA P16234 1/20 0.34
CYP2A6 P11509 3/20 0.33
CYP2B6 P20813 2/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
GAA P10253 3/20 0.33
CYP11B1 P15538 2/20 0.32
CYP11B2 P19099 2/20 0.32
PPARA Q07869 1/20 0.32
AR P10275 1/20 0.32
CYP2E1 P05181 1/20 0.32
FYN P06241 1/20 0.31
TDO2 P48775 1/20 0.31
CYP17A1 P05093 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2968218 0.81 PDE10A (0.42) PDE10AKCNN1KCNN2KCNN3
SCHEMBL5468136 0.76 PDE10A (0.53) PDE10AKCNN1KCNN2KCNN3PDGFRB
SCHEMBL8640233 0.76 GAA (0.48) PDGFRBPDGFRACYP2A6CYP2B6GAA
SCHEMBL2978671 0.73 KDR (0.40) PDGFRBPDGFRACYP2A6CYP2B6CYP3A4
SCHEMBL5445358 0.71 CHRM2 (0.34)
SCHEMBL5460463 0.70 CDK2 (0.41) CYP2C19GAAARTDO2TP53
SCHEMBL1487743 0.69 PDE10A (0.47) PDE10AKCNN1KCNN2KCNN3
SCHEMBL13225458 0.67 PDE10A (0.41) PDE10AKCNN1KCNN2KCNN3CYP17A1
SCHEMBL4334107 0.66 PDE10A (0.47) PDE10AKCNN1KCNN2KCNN3CYP2C9
SCHEMBL5445372 0.66 PDE10A (0.43) PDE10AKCNN1KCNN2KCNN3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2396330-B1 FUSED PYRIMIDINES BAYER IP GMBH (DE) 2016-04-06 EP disclosed
US-8957064-B2 Fused pyrimidines BAYER INTELLECTUAL PROPERTY GMBH (US) 2015-02-17 US disclosed
US-8614218-B2 Fused bicyclic pyrimidines BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-12-24 US disclosed
US-20130317002-A1 FUSED PYRIMIDINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2013-11-28 US disclosed
EP-2188291-B1 FUSED BICYCLIC PYRIMIDINES Bayer Pharma AG (DE) 2012-09-19 EP disclosed
US-7776864-B2 Fused bicyclic pyrimidines BAYER SCHERING PHARMA AG (DE) 2010-08-17 US disclosed
US-20100184782-A1 FUSED BICYCLIC PYRIMIDINES BAYER INTELLECTUAL PROPERTY GMBH (DE) 2010-07-22 US disclosed
US-20090137607-A1 FUSED BICYCLIC PYRIMIDINES BAYER INTELLECTUAL PROPERTY GMBH (DE) 2009-05-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137607-A1 FUSED BICYCLIC PYRIMIDINES PIK3CA, TYMS, MTOR PDE10A 3014/4885KCNN1 4544/4885KCNN2 4573/4885
US-20130317002-A1 FUSED PYRIMIDINES PIK3CA, MTOR, TYMS PDE10A 1997/4885KCNN1 4328/4885KCNN2 4327/4885
US-20100184782-A1 FUSED BICYCLIC PYRIMIDINES PIK3CA, TYMS, MTOR PDE10A 3014/4885KCNN1 4544/4885KCNN2 4573/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.